Acro Biomedical Co., Ltd.
ACBM
$0.03
$0.0017.12%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 305.26% | 220.48% | -96.62% | -98.55% | -99.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 305.26% | 220.48% | -97.45% | -99.24% | -99.57% |
| Operating Income | -305.26% | -220.48% | 97.45% | 99.24% | 99.57% |
| Income Before Tax | -139.24% | -210.04% | 97.13% | 99.14% | 99.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -139.24% | -210.04% | 97.13% | 99.14% | 99.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.24% | -210.04% | 97.13% | 99.14% | 99.52% |
| EBIT | -305.26% | -220.48% | 97.45% | 99.24% | 99.57% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -125.00% | -200.00% | 96.69% | 99.00% | 99.45% |
| Normalized Basic EPS | -325.00% | -220.00% | 97.02% | 99.20% | 99.56% |
| EPS Diluted | -125.00% | -200.00% | 96.69% | 99.00% | 99.45% |
| Normalized Diluted EPS | -325.00% | -220.00% | 97.02% | 99.20% | 99.56% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |